AUGUSTA, Maine — Maine will receive about $445,000 of a multistate $35 million settlement with Pfizer Inc. to resolve allegations that its parent company Wyeth unlawfully promoted Rapamune, a drug used to prevent organ rejection after kidney transplant surgery, according to Attorney General Janet Mills.

Maine’s portion of the money will be used to further consumer health education efforts, Mills said Friday in a press release.

The consent judgment, according to Mills, alleged that Wyeth violated state consumer protection laws by misrepresenting the uses and benefits of Rapamune, including making representations related to: the unapproved use of Rapamune following an organ transplant other than a kidney transplant; the unapproved protocol of converting patients to Rapamune after initially receiving a different immunosuppressive drug; and using Rapamune in unapproved drug combinations.

“Improper marketing of pharmaceuticals is not only a waste of healthcare dollars, it can put patients at risk, as well,” she said. “I am pleased that Maine was able to work with other state attorneys general to hold this company accountable. These efforts will deter misuse of pharmaceuticals in our state.”

Maine and 40 other states participated in the settlement, the press release said.